文献速递脊柱关节炎

早期银屑病关节炎TICOPA试验的长期随访

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究对完成TICOPA试验的110例患者进行病例回顾,评估严格达标治疗(TC)组与标准治疗(StdC)组的长期临床优势是否持续。结果显示约五年后两组疾病活动度相似(当前低疾病活动度TC 69%、StdC 76%),生物制剂使用比例趋同(TC 54%、StdC 52%),甲氨蝶呤使用减少,TC未带来长期额外获益。

要点

  • TICOPA试验完成约五年后,TC组与StdC组低疾病活动度比例相似(69% vs 76%)。
  • 研究结束时TC组生物制剂使用更高(33% vs 9%),但随访时两组趋同(54% vs 52%)。
  • TC策略未导致长期生物制剂使用增加,两组甲氨蝶呤使用均减少。

核心结论

  • TICOPA试验中严格达标治疗(TC)带来的临床优势在干预结束后数年未能持续,长期临床结局与标准治疗(StdC)相似。

研究设计与样本

  • 对完成TICOPA试验的患者队列进行病例回顾,共纳入110例(TC组54例,StdC组56例)。

主要发现

  • 随访时低疾病活动度(无压痛或肿胀关节、无指趾炎和附着点炎、无需改变治疗)比例TC组69%、StdC组76%。
  • 研究结束时生物制剂使用TC组33%、StdC组9%,随访时TC组54%、StdC组52%。
  • 随访时两组甲氨蝶呤使用均减少。

关键数值与推荐

  • 低疾病活动度定义为无压痛或肿胀关节、无指趾炎和附着点炎、且无需改变治疗。

临床怎么用

  • 早期银屑病关节炎采用严格达标治疗可在试验期间改善结局,但长期随访未显示持续临床优势,生物制剂使用亦未因TC策略而长期增加。

局限性

  • 本研究为病例回顾性队列研究,仅纳入完成TICOPA试验的部分患者,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) study was the first strategy trial in psoriatic arthritis using an early treat-to-target strategy to improve clinical outcomes. The current study aimed to review a cohort of patients who had completed TICOPA to judge if the clinical advantage gained by participants in the tight control (TC) arm was sustained, and to explore subsequent therapy. METHODS: A case note review was conducted for a cohort of patients who had participated in TICOPA. Current drug use and clinical status were obtained, with low disease activity judged as no tender or swollen joints, no dactylitis and enthesitis, and no change in treatment required. RESULTS: Approximately five years after completion of the TICOPA study, notes were reviewed for 110 patients [TC, n = 54; standard care (StdC), n = 56]. Disease activity was found to be similar in both groups (current low disease activity: TC 69%, StdC 76%). Biologic use at the end of the study was higher in the TC arm (TC 33%, StdC 9%), but at review a similar percentage in both groups were taking biologic drugs (TC 54%, StdC 52%), whereas MTX use diminished. CONCLUSION: After several years, clinical outcomes and therapeutic drug use were similarly good for patients in both arms of the TICOPA study, with no obvious clinical advantage after TC ended. Notably, TC did not result in greater biological use long term, and MTX use decreased in both arms of the study.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Coates LC, Mahmood F, Freeston J, et al. Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Rheumatology (Oxford). 2020. PMID: 31504996. doi:10.1093/rheumatology/kez369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。